Elicio Therapeutics Files 8-K on Security Holder Vote Matters
Ticker: ELTX · Form: 8-K · Filed: Nov 21, 2024 · CIK: 1601485
| Field | Detail |
|---|---|
| Company | Elicio Therapeutics, Inc. (ELTX) |
| Form Type | 8-K |
| Filed Date | Nov 21, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
Related Tickers: ELIO
TL;DR
ELIO filed an 8-K for a shareholder vote - watch for updates on corporate actions.
AI Summary
Elicio Therapeutics, Inc. filed an 8-K on November 21, 2024, to report on the submission of matters to a vote of security holders. The company, formerly known as Angion Biomedica Corp., is incorporated in Delaware and headquartered in Boston, Massachusetts.
Why It Matters
This filing indicates that Elicio Therapeutics is seeking shareholder approval for certain corporate actions, which could impact the company's strategic direction and future operations.
Risk Assessment
Risk Level: low — The filing is procedural, reporting on a vote of security holders, and does not disclose new financial or operational risks.
Key Players & Entities
- Elicio Therapeutics, Inc. (company) — Registrant
- Angion Biomedica Corp. (company) — Former company name
- November 21, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Boston, Massachusetts (location) — Principal executive offices
FAQ
What specific matters are being submitted for a vote of security holders?
The filing does not specify the exact matters to be voted on, only that the 8-K is being filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 concerning the submission of matters to a vote of security holders.
When was Elicio Therapeutics, Inc. formerly known as Angion Biomedica Corp.?
The date of the name change from Angion Biomedica Corp. to Elicio Therapeutics, Inc. was February 28, 2014.
What is the IRS Employer Identification Number for Elicio Therapeutics, Inc.?
The IRS Employer Identification Number for Elicio Therapeutics, Inc. is 11-3430072.
What is the SEC file number for Elicio Therapeutics, Inc.?
The SEC file number for Elicio Therapeutics, Inc. is 001-39990.
What is the business address and phone number of Elicio Therapeutics, Inc.?
The business address is 451 D Street, 5th Floor, Boston, Massachusetts 02210, and the telephone number is (857) 209-0050.
Filing Stats: 741 words · 3 min read · ~2 pages · Grade level 12.8 · Accepted 2024-11-21 16:06:26
Key Financial Figures
- $0.01 — nge on which registered) Common Stock, $0.01 par value per share ELTX The Nasdaq Cap
Filing Documents
- angn-20241121.htm (8-K) — 33KB
- 0001601485-24-000083.txt ( ) — 159KB
- angn-20241121.xsd (EX-101.SCH) — 2KB
- angn-20241121_lab.xml (EX-101.LAB) — 22KB
- angn-20241121_pre.xml (EX-101.PRE) — 13KB
- angn-20241121_htm.xml (XML) — 3KB
07. Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders. On November 21, 2024, Elicio Therapeutics, Inc. (the "Company") held its 2024 annual meeting of stockholders (the "Annual Meeting"). At the Annual Meeting, the stockholders of the Company considered and voted on three proposals, each of which was described in detail in the Company's definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission on September 27, 2024 (the "Proxy Statement"). 7,452,994 shares of Common Stock voted, representing 69.17% of the voting power of all shares entitled to vote at the Annual Meeting, which represented a quorum for the Annual Meeting. At the Annual Meeting, the stockholders voted on proposals to: (1) elect three directors to hold office for three-year terms, (2) ratify the appointment of Baker Tilly US, LLP, as the Company's independent registered public accounting firm for the fiscal year ending 2024, and (3) approve, for purposes of complying with Nasdaq Listing Rule 5635(b), the issuance of shares of common stock issuable upon the exercise of certain warrants and conversion of that certain convertible note, as further detailed in the Proxy Statement. Set forth below are the final voting results for each proposal submitted to a vote of the stockholders at the Annual Meeting. More information on the proposals can be found in the Proxy Statement. Proposal 1 : To elect three nominees to serve as the Company's Class I Directors to hold office for a three-year term or until their respective successors are elected and qualified. Nominee For Against Abstain Broker Non-Votes Robert Connelly 6,248,397 103,851 15,167 1,085,579 Yekaterina (Katie) Chudnovsky 6,233,264 118,343 15,706 1,085,681 Allen R. Nissenson, M.D. 6,249,739 102,488 15,086 1,085,681 Proposal 2 : To ratify the appointment of Baker Tilly US, LLP as the Company's independent registered public accounting firm for the fiscal year ending 2024. For Against Abstain Brok
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Elicio Therapeutics, Inc. By: /s/ ROBERT CONNELLY Date: November 21, 2024 Robert Connelly President and Chief Executive Officer (Principal Executive Officer, Principal Financial Officer, and Principal Accounting Officer)